Technical Principles and Application Value of Protein S Activity Assay Kit (Clotting Method) in Screening for Thrombotic Diseases

Principle and Advantages of Clotting-Based Protein S Activity Assay

Protein S is a vitamin K-dependent anticoagulant protein that exists in vivo in both free and bound forms. Free protein S serves as a cofactor for activated protein C (APC) and exerts its anticoagulant effect by inactivating coagulation factors Va and VIIIa. The protein S activity assay kit (clotting method) is based on the principle of APC resistance: APC and activated partial thromboplastin time (APTT) reagent are added to the test plasma, and protein S activity is reflected by the degree of prolongation of clotting time. Generally, the higher the protein S activity, the more pronounced the prolongation of clotting time; conversely, it is shortened. This method directly detects functional activity and can simultaneously reflect the total anticoagulant function of both free and bound protein S, offering irreplaceable value for the clinical diagnosis of hereditary or acquired protein S deficiency. Unlike immunological methods (such as ELISA), which only detect antigen levels, the clotting method detects functional activity and better reflects the true anticoagulant status in vivo, and is particularly more sensitive in conditions affecting protein S synthesis and consumption, such as liver disease, oral anticoagulant use, or the acute phase of thrombosis. In addition, the clotting method is rapid to perform and suitable for automated coagulation analyzers, enabling high-throughput, standardized testing, and has been adopted by most clinical laboratories.

Clinical Application Scenarios and Key Points for Result Interpretation

Protein S activity testing is one of the important items in thrombophilia screening. For unexplained deep vein thrombosis, pulmonary embolism, recurrent miscarriage, or thrombotic events in young patients, clinical guidelines often recommend thrombophilia screening including protein C, protein S, and antithrombin. The results of the protein S activity assay kit (clotting method) should be comprehensively judged in combination with the patient's age, sex, physiological status, and medication use. For example, pregnant women, oral contraceptive users, and patients with liver disease may show acquired decreases in protein S; whereas protein S levels may be lower in neonates and children. The clotting method used in the test system has high requirements for sample quality, and attention should be paid to the anticoagulant-to-blood ratio in the collection tube (generally 3.2% sodium citrate, 1:9), centrifugation conditions (4°C, 3000g for 15 minutes), and avoidance of hemolysis and lipemia. Before testing, vitamin K antagonists such as warfarin should be discontinued for at least 2 weeks. Reference intervals are generally established by the laboratory itself or cited from manufacturer recommendations, but differences may exist among different kits and instruments, and it is recommended to note the methodology in the report. If activity is decreased but antigen is normal, it suggests a functional defect; if both activity and antigen are low, it suggests quantitative deficiency. Repeat testing can improve diagnostic reliability.

Quality Control and Standardization Challenges of the Kit

Currently, commercially available protein S activity assay kits (clotting method) mostly use pooled freeze-dried plasma from healthy individuals as calibrators, establishing a relationship curve between clotting time and percentage activity through multi-point calibration. Internal quality control should include both normal and pathological levels and participate in external quality assessment. It is worth noting that the clotting method is susceptible to interference from insufficient coagulation factors, lipemia, heparin contamination, and other factors, leading to falsely elevated or decreased results. In recent years, the widespread use of automated coagulation analyzers has improved testing precision, but the comparability of results among different testing systems still needs to be evaluated using international standards (such as WHO standards). With technological improvements in domestic reagents, some products have obtained registration from the National Medical Products Administration, providing more options for clinical use. When introducing a kit, laboratories should perform methodological validation, including precision, accuracy, linear range, etc., to ensure that performance meets clinical needs. Regular participation in external quality assessment and traceability of calibrators helps improve consistency of results among different laboratories.